obesity drug

Pfizer Inc. (NYSE:PFE) secured a $10 billion deal to acquire obesity drug developer Metsera, Inc. (NASDAQ:MTSR), beating out Novo Nordisk A/S (NYSE:NVO) after a heated bidding war that captivated Wall Street. Metsera Board Backs Deal Under the deal, Pfizer will pay $86.25 per share, consisting of $...

Viking Therapeutics Inc. (NASDAQ:VKTX) is nearing a pivotal moment as its stock hovers just above a potential death cross. This ominous technical pattern, where the 50-day moving average moves below the 200-day moving average, is often seen as a bearish signal. While not confirmed yet, the...

JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics Inc (NASDAQ:VKTX) with an Overweight rating and a December 2025 price target of $80, which implies a potential 45% upside from its current price of $54.65. At the core of this bullish outlook is Viking’s obesity drug...

Cathie Wood-run Ark Invest on Friday picked up shares of a biopharma company after it revealed significant progress with its weight-loss drug candidate. What Happened: Ark, through its ARK Genomic Revolution ETF (CBOE: ARKG), bought 11,360 shares of Amgen, Inc. (NASDAQ:AMGN), which rallied nearly...

Eli Lilly & Co. (NYSE:LLY) has been a high-flier among the mega-cap pharma stocks this year, as the company leverages the obesity drug craze. Prominent Tesla investor and Future Fund Manager Gary Black weighed in on the stock’s run-up and its future trajectory. What Happened: Lilly stock...